Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
Robert P. Perrillo, Ching‐Lung Lai, Yun‐Fan Liaw, Jules L. Dienstag, Eugene R. Schiff, Solko W. Schalm, E. Jenny Heathcote, Nathaniel A. Brown, Mark Atkins, Mary Woessner, Stephen D. Gardner – 30 December 2003 – Elevated alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatitis B treated with interferon. Predictors of HBeAg loss in patients treated with lamivudine are not known.